Episode Summary
In this episode, Prof Nick Pavlakis and Prof Stephen Fox discuss Next-generation sequencing (NGS) based tumour comprehensive genomic profiling (CGP) that detects a wide range of genomic aberrations. The value of CGP for lung cancer patients in Australia will be discussed including the TOGA ASPiRATION study, an observational cohort study to assess the clinical impact of CGP in metastatic lung cancer patients. Drugs that target cancer gene mutations or rearrangements have improved outcomes for patients with many different cancers, including lung cancer, melanoma, and others. The challenge is being able to identify these genomic changes in a timely and efficient manner. NGS based tumour CGP that detects a wide range of genomic aberrations is one method being utilized to match patients to relevant targeted therapies against several oncogenic drivers, particularly for lung cancer. Several in-house, as well as commercial testing panels, are now available that help Medical Oncologists understand the cancer genomic profile of their patients. This information helps inform whether there these patients are likely to respond to a targeted agent, either as standard of care or as part of a clinical trial. In this Podcast, we will discuss some of the challenges that exist in being able to identify these molecular changes.
https://thoraciconcology.org.au/aspiration/
Thank you to Roche for sponsoring this Podcast.
Show Hosts
This episode’s host are:
- Prof Nick Pavlakis, Chair, TOGA; Senior Staff Specialist, Department of Medical Oncology, Royal North Shore Hospital
- Prof Stephen Fox, Head of the Molecular Pathology Library; Director of Pathology, Peter MacCallum Cancer Institute; Professional Fellow, Department of Pathology, University of Melbourne
